693287-79-5

Basic information

• Product Name: Hydrazinecarboxylic acid, 2-(tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester
• Synonyms: N'-(Oxan-4-yl)(tert-butoxy)carbohydrazide;1-Boc-2-(4-tetrahydropyranyl)hydrazine;tert-Butyl 2-(tetrahydro-2H-pyran-4-yl);Hydrazinecarboxylic acid, 2-(tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester;t-Butyl 2-(tetrahydro-2H-pyran-4-yl)hydrazinecarboxylate;tert-butyl 2-(tetrahydro-2H-pyran-4-yl)hydrazinecarboxylate;2-(Tetrahydro-2H-pyran-4-yl)hydrazinecarboxylic acid 1,1-dimethylethyl ester;2-(Tetrahydropyran-4-yl)hydrazinecarboxylic acid tert-butyl ester
• CAS NO: 693287-79-5
• Molecular Formula: C₁₀H₂₀N₂O₃
• Molecular Weight: 216.2774
• Product Categories: N-BOC
• Mol File: 693287-79-5.mol
• Article Data: 26

Chemical Properties

• Appearance: /
• Density: 1.07
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Hydrazinecarboxylic acid, 2-(tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Hydrazinecarboxylic acid, 2-(tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester(693287-79-5)
• EPA Substance Registry System: Hydrazinecarboxylic acid, 2-(tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester(693287-79-5)

Safety Data

• Hazardous Substances Data: 693287-79-5(Hazardous Substances Data)

Usage

General Description

Hydrazinecarboxylic acid, 2-(tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester is a chemical compound that is commonly known as tert-Butyl (2S)-2-(tetrahydro-2H-pyran-4-yl)hydrazinecarboxylate. It is an ester derivative of hydrazinecarboxylic acid, and it is often used in organic synthesis and pharmaceutical research. Hydrazinecarboxylic acid, 2-(tetrahydro-2H-pyran-4-yl)-, 1,1-dimethylethyl ester has potential biological activity and may be used in the development of new drugs. It is important to handle this chemical with care and follow safety protocols, as it can be hazardous if not used properly.

InChI:InChI=1S/C10H20N2O3/c1-10(2,3)15-9(13)12-11-8-4-6-14-7-5-8/h8,11H,4-7H2,1-3H3,(H,12,13)

Upstream product

• 693287-78-4 N’-(tetrahydropyran-4-ylidene)hydrazinecarboxylic acid tert-butyl ester 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 870-46-2 t-butoxycarbonylhydrazine 
• 64-19-7 acetic acid 

Downstream Products

• 116312-69-7 tetrahydro-2H-pyran-4-yl-hydrazine 
• 693287-81-9 methyl 5-(4-methylthiophenyl)-1-(tetrahydro-2H-pyran-4-yl)pyrazole-3-carboxylate 
• 693287-83-1 [5-(4-methanesulfonyl-phenyl)-1-(tetrahydro-pyran-4-yl)-1H-pyrazol-3-yl]-methanol 
• 693287-82-0 methyl 5-[(4-methylsulfonyl)phenyl]-1-(tetrahydro-2H-pyran-4-yl)pyrazole-3-carboxylate 
• 1082744-06-6 6-((3S,4S)-1-benzyl-4-ethylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082744-07-7 6-((3S,4S)-1-(2-fluorobenzyl)-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082743-98-3 6-((3S,4S)-1-(3-fluorobenzyl)-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082744-05-5 6-((3S,4S)-1-(4-fluorobenzyl)-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082744-10-2 6-((3S,4S)-1-(4-methoxybenzyl)-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082744-20-4 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1189767-09-6 6-benzyl-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082745-49-0 5-amino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carbonitrile 
• 1082745-50-3 5-amino-1-(tetrahydropyran-4-yl)-1H-pyrazole-4-carboxylic acid amide 
• 1082743-70-1 6-((3S,4S)-1-benzyl-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 

Relevant articles and documents

PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12

The present invention provides compounds of general formula (I) in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

Growth Factor Receptor antagonists. Preparation method and application thereof

The invention relates to a small molecule antagonist for transforming growth factor β receptors, a method for preparing the small molecule antagonist, and application of the small molecule antagonist in preparation of drugs. The small molecule antagonist for transforming the growth factor β receptor has the application of treating and/or preventing various diseases mediated by ALK5, and has great clinical application potential.